FE 999049: Clinical Trials

13 trials of FE 999049, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 1 terminated. 9 Phase 3, 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 39Completed 9
Phase 23Completed 2, Terminated 1
Phase 11Completed 1

Follow FE 999049: new trials by email Literature Review of FE 999049 trials Research Report on FE 999049

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China
FE 999049, GONAL-F - Infertility, Female
Phase 3CompletedFerring Pharmaceuticals3012024-03-292026-02-12
A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)
FE 999049, Placebo - Male Idiopathic Infertility
Phase 2TerminatedFerring Pharmaceuticals42022-08-162026-08-28
Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Indian Women
Follitropin Delta (FE 999049), Follitropin Alfa (GONAL-F) - Infertility
Phase 3CompletedFerring Pharmaceuticals2202021-12-032025-01-24
Rekovelle PK Trial in Chinese Women
Follitropin Delta - Infertility
Phase 1CompletedFerring Pharmaceuticals242019-06-232023-02-14
Follitropin Delta in Long GnRH Agonist and GnRH Antagonist Protocols (BEYOND)
FE 999049 + GnRH agonist (GONAPEPTYL), FE 999049 + GnRH antagonist (CETROTIDE) - Infertility, Female
Phase 3CompletedFerring Pharmaceuticals4372019-04-292024-05-13
Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)
Follitropin delta, Placebo - Infertility, Female
Phase 3CompletedFerring Pharmaceuticals5882018-10-292024-01-18
Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)
Follitropin delta, Placebo - Infertility
Phase 3CompletedFerring Pharmaceuticals5792018-10-262024-01-18
Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women
Follitropin alfa, Follitropin delta - Controlled Ovarian Simulation
Phase 3CompletedFerring Pharmaceuticals10112017-12-012023-08-24
Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women
Follitropin delta, Follitropin beta - Infertility
Phase 3CompletedFerring Pharmaceuticals3732017-07-292023-08-24
A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment
FE 999049, follitropin beta - Infertility
Phase 2CompletedFerring Pharmaceuticals1592014-12-012020-12-14
Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2
Follitropin Delta (FE 999049), Follitropin Alfa (GONAL-F) - Infertility
Phase 3CompletedFerring Pharmaceuticals5132014-03-262023-09-06
Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1
Follitropin Delta (FE 999049), Follitropin Alfa (GONAL-F) - Infertility
Phase 3CompletedFerring Pharmaceuticals13292013-10-012022-01-13
A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment
FE 999049, Gonal - F - Infertility
Phase 2CompletedFerring Pharmaceuticals2652011-09-012020-11-17

Conditions studied

Infertility (8)  ·  Infertility, Female (3)

Sponsors

Ferring Pharmaceuticals (13)

Countries

Denmark (5)  ·  Belgium (4)  ·  Italy (4)  ·  Spain (4)  ·  China (3)  ·  Czechia (3)  ·  United States (3)  ·  Brazil (2)  ·  Canada (2)  ·  France (2)  ·  Japan (2)  ·  Poland (2)  ·  Russia (2)  ·  United Kingdom (2)  ·  Austria (1)

Results publications

PMID 37156263, PMID 30801744, PMID 32819842, PMID 34254211, PMID 34799275, PMID 40714031, PMID 25256937, PMID 27912901, PMID 33272623, PMID 33722477, PMID 34179971, PMID 36195924, PMID 36478528, PMID 38723189

NIH funding

2017 (1)